Solidity remains the dominant smart contract language for Ethereum and EVM-compatible chains, with the 2025 developer survey collecting responses from developers across eighty-seven different ...

Fox Tempest is a financially motivated threat actor operating a malware‑signing‑as‑a‑service (MSaaS) used by other ...

Companies are scrambling to deal with the glut. Credit...Mojo Wang Supported by By Mike Isaac and Erin Griffith Reporting from San Francisco When a financial services company recently began using ...

Microsoft says Agent Framework 1.0 is the production-ready release, with stable APIs and long-term support for both .NET and Python. The framework is presented as a unified successor path that builds ...

VentureBeat made with Google Gemini 3.1 Pro Image Anthropic appears to have accidentally revealed the inner workings of one of its most popular and lucrative AI products, the agentic AI harness Claude ...

The White House on Friday released its long-awaited national artificial intelligence legislative framework, a move to prevent states from enacting their own laws and enforce the Trump administration’s ...

With Claude enjoying a moment of newfound popularity among regular people, Anthropic is previewing an update designed to make its chatbot better at explaining some concepts. Starting today, Claude can ...

When it comes to coding, peer feedback is crucial for catching bugs early, maintaining consistency across a codebase, and improving overall software quality. The rise of “vibe coding” — using AI tools ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Dany Lepage discusses the architectural ...

Within three years, no embedded software developer is going to be writing code. I know it sounds like another one of my controversial statements. But I recently used Claude Code to write the best ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...